Drug intelligence / Profile preview

IME0001

Development stage: Unknown
Lead developer: IMIDomics
Modality: Small Molecules
Administration: Oral

Overview

IME0001 (formerly GS-2730) is an orally bioavailable small molecule inhibitor of diacylglycerol kinase zeta (DGKζ), a key regulator of diacylglycerol (DAG) signaling in immune cells. By inhibiting DGKζ, the drug enhances DAG-mediated signaling, which can modulate T-cell activation and function. Originally developed by Gilead Sciences and licensed to IMIDomics in 2024, IME0001 is being developed for the treatment of immune-mediated inflammatory diseases (IMIDs), with a primary focus on Systemic Lupus Erythematosus (SLE). It is currently in clinical development, having completed initial Phase 1 safety and tolerability studies under Gilead before transitioning to IMIDomics for further clinical evaluation.

Targets

DGKZ (Diacylglycerol kinase zeta)

Beyond the preview

Go deeper on IME0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IME0001.

Explore the full profile